4baseCare
Together, We Beat Cancer

TARGT® Indiegene

Solid

Differentiated by Science | Designed for Diversity | Built for Precision.

TARGT Indiegene redefines Comprehensive Genomic Profiling with DNA & RNA Exome sequencing, enabling deeper molecular characterization and enhanced detection of actionable biomarkers across globally diverse and underrepresented populations.



CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

The Indiegene Advantage

COMPREHENSIVE COVERAGE OF 1212 GENES AND 5.27 MB PANEL SIZE

WHY TARGT INDIEGENE SOLID?

Comprehensive Genomic Profiling (CGP):

Broad analysis of clinically relevant genomic alterations, including SNVs, Indels, CNAs, and gene fusions in a single assay

Enhanced Fusion Detection:

Covers 299 fusion events, enabling identification of actionable fusion-driven cancers

Advanced TMB Assessment:

Provides refined whole exome equivalent Tumor Mutational Burden (TMB) evaluation using percentile-based scoring for more meaningful interpretation

High Sensitivity Detection:

Robust identification of low-frequency and rare genomic variants, maximizing actionable findings

Prognostic, Predictive & Pharmacogenomic Insights:

Identifies biomarkers associated with therapeutic response, drug resistance, disease progression, and clinical outcomes to support informed treatment decisions

Comprehensive Pathway Coverage:

Evaluates major cancer-associated pathways to support precision treatment decisions

Key Features & Differentiators

CGP WITHOUT BOUNDARIES, DESIGNED FOR DIVERSE POPULATIONS

TARGT Indiegene includes all guideline-recommended biomarkers (NCCN, ESMO, FDA) and investigational targets, supporting both standard-of-care and exploratory treatment decisions.

Comprehensive Variant Detection

- Delivers higher sensitivity and accuracy for Globally Diverse and underrepresented populations
- Reflects region-specific mutational frequencies and oncogenic drivers
- Includes all globally recognized actionable biomarkers for global clinical relevance

Most Comprehensive in Its Class

1212 Genes | 5.27 Mb panel size | Unmatched Breadth
Setting a new benchmark in comprehensive profiling, TARGT Indiegene covers:

- 1212 genes, including all NCCN, ESMO, and FDA-approved biomarkers
- Investigational and emerging markers for advanced therapy decisions
- A panel size of ~5.27 Mb which is ~3x the size of other commercially available panels

Individualized TMB Scoring

A First-of-Its-Kind Personalized Immunotherapy Marker
One size doesn't fit all. Our research, published in ASCO-JCO PO, revealed:

- TMB thresholds vary by cancer type and ethnicity
- Fixed cutoffs (like 10 mutations/Mb) risk misclassification
- TARGT Indiegene introduces Individualized TMB Percentile Scoring

Advanced Fusion Detection

299 Fusions | 91 novel driver fusions | Unrivaled Innovation
Where most commercial panels cover <100 fusions, TARGT Indiegene goes beyond

- Detects 299 fusion events, including ALK, NTRK, ROS1, RET, and more
- Features 91 novel driver fusions, including those involving FGFR2, ESR1, and PDGFRA
- Proprietary fusion database under provisional patent, ensuring clinical edge

Assay Specification and Performance Overview

Gene Number
1212 Genes

Sample Type
FFPE Tissue block ideally not more than 5 months old, Fresh Frozen Tissue, with > 20% Tumor content

Specificity and Sensitivity
99.99%

Turn Around Time
12-14 working days

Sequencing Chemistry
Hybrid Capture, End to End Sequencing of all the Exons of a given Gene

Mean Sequencing Depth
2000X

Revolutionising Care, Personalising Hope Globally

With Precision Oncology, we're not just treating cancer. We're redefining what's possible in Cancer care.

*Together, **We Beat** Cancer*

India Nepal Philippines UAE

4baseCare
Together, We Beat Cancer

For any further information on 4baseCare Solutions and Services, please contact:

4basecare.com +91 636-684-3415 info@4basecare.com

3rd floor, Summit B, Brigade Metropolis, Garudachar Palya, Bengaluru, Karnataka 560048